BE860169A - Thymosine alpha1 - Google Patents

Thymosine alpha1

Info

Publication number
BE860169A
BE860169A BE182108A BE182108A BE860169A BE 860169 A BE860169 A BE 860169A BE 182108 A BE182108 A BE 182108A BE 182108 A BE182108 A BE 182108A BE 860169 A BE860169 A BE 860169A
Authority
BE
Belgium
Prior art keywords
thymosin alpha1
alpha1
thymosin
Prior art date
Application number
BE182108A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Univ Texas filed Critical Hoffmann La Roche
Publication of BE860169A publication Critical patent/BE860169A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57581—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/18—Thymus derived hormone or factor; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BE182108A 1976-10-28 1977-10-27 Thymosine alpha1 BE860169A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73663876A 1976-10-28 1976-10-28

Publications (1)

Publication Number Publication Date
BE860169A true BE860169A (fr) 1978-04-27

Family

ID=24960663

Family Applications (1)

Application Number Title Priority Date Filing Date
BE182108A BE860169A (fr) 1976-10-28 1977-10-27 Thymosine alpha1

Country Status (4)

Country Link
US (1) US4079127A (fr)
BE (1) BE860169A (fr)
HU (1) HU172798B (fr)
ZA (1) ZA775976B (fr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4116951A (en) * 1977-04-22 1978-09-26 Hoffmann-La Roche Inc. [Asn2 ]-thymosin α1 and analogs thereof
US4680276A (en) * 1977-05-25 1987-07-14 Institut National De La Sante Et De La Recherche Medicale Metal polypeptides
US4264571A (en) * 1979-01-22 1981-04-28 George Washington University Radioimmunoassay of thymosin α1
US4297276A (en) * 1979-03-23 1981-10-27 Hoffman-La Roche Inc. Thymosin beta 3 and beta 4
US4261886A (en) * 1980-03-13 1981-04-14 Ortho Pharmaceutical Corporation Peptides having thymopoietin-like activity
DE2919592A1 (de) * 1979-05-15 1981-01-15 Max Planck Gesellschaft Verfahren zur herstellung von thymosin- alpha 1 und derivaten davon
EP0033384B1 (fr) * 1980-01-18 1984-02-15 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Médicaments contenant des fragments de thymosine-alpha-1, leur activité immunostimulante, et fragments de thymosine-alpha-1
JPS56138154A (en) * 1980-02-28 1981-10-28 Genentech Inc Desacetylthymosin-alpha-1 and manufacture
US4361673A (en) * 1980-09-19 1982-11-30 American Home Products Corporation Polypeptide compositions
SE448605B (sv) * 1980-10-27 1987-03-09 Vtoroi Mo G Med I Imen Terapeutiskt preparat for reglering av t-immunsystemet och forfarande for framstellning derav
JPS57110196A (en) * 1980-10-30 1982-07-08 Hoffmann La Roche Preparation of thimocin alpha 1
US4444757A (en) * 1981-11-16 1984-04-24 Research Corporation Use of thymosin as an anti-diabetes and anti-hypertensive disease agent
US4388234A (en) * 1981-12-28 1983-06-14 Hoffmann-La Roche Inc. Peptide isolation
DE3230151A1 (de) * 1982-08-13 1984-02-16 Hoechst Ag, 6230 Frankfurt Neues polypeptid mit wirkung auf das immunsystem, verfahren zu seiner isolierung und reinigung, seine verwendung, dieses enthaltende mittel sowie seine spaltprodukte, deren verwendung und diese enthaltende mittel
US4504415A (en) * 1983-04-04 1985-03-12 Hoffman-La Roche Inc. Synthesis of thymosin α1 and desacetyl thymosin α1
US4517119A (en) * 1983-04-04 1985-05-14 Hoffmann-La Roche Inc. Synthesis of thymosin α1
US4543340A (en) * 1983-04-07 1985-09-24 George Washington University Radioimmunoassay of thymosin β4
US4614731A (en) * 1983-09-15 1986-09-30 Hoffmann-La Roche Inc. Peptide having immunopotentiating activity similar to thymosin alpha1
US4621135A (en) * 1983-12-08 1986-11-04 Yeda Research & Development Company, Ltd. Novel THF compositions
US4983387A (en) * 1986-05-19 1991-01-08 Viral Technologies Inc. HIV related peptides, immunogenic antigens, and use therefor as subunit vaccine for AIDS virus
US4777239A (en) * 1986-07-10 1988-10-11 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic peptides of human papilloma virus
US5728680A (en) 1987-12-30 1998-03-17 Cytoven J.V. Methods for normalizing numbers of lymphocytes
US5807830A (en) * 1987-12-30 1998-09-15 Cytoven J.V. Method for treatment of purulent inflammatory diseases
US5811399A (en) * 1988-12-14 1998-09-22 Cytran, Inc. Pharmaceutical dipeptide compositions and methods of use thereof: immunodepressants
US5770576A (en) * 1989-08-30 1998-06-23 Cytran, Inc. Pharmaceutical dipeptide compositions and methods of use thereof: systemic toxicity
EP0570478A4 (en) * 1991-02-04 1994-08-17 Univ George Washington Mb-40 peptide that enhances the production of interleukin-1 and modulates age-associated immune response
US5273963A (en) * 1991-03-29 1993-12-28 The George Washington University Compositions and methods for treating small cell and nonsmall cell lung cancers
US6066622A (en) 1991-10-28 2000-05-23 Cytran, Inc. Immunomodulating peptides and methods of use
US6100380A (en) * 1991-10-28 2000-08-08 Cytran, Inc. Immunomodulating peptides and methods of use
EP0728010A4 (fr) * 1992-02-06 1997-10-01 Sciclone Pharmaceuticals Methode de traitement de porteurs de l'hepatite b presentant un etat pathologique minime
US5308833A (en) * 1992-02-06 1994-05-03 Sciclone Pharmaceuticals Method for treating hepatitis B carriers with minimal disease
CN1058500C (zh) * 1993-02-03 2000-11-15 施塞克龙药品公司 胸腺素α－1衍生物
AU6359594A (en) * 1993-03-04 1994-09-26 Cytoven International N.V. Pharmaceutical tryptophan containing dipeptide compositions and methods of use thereof
US6200952B1 (en) * 1993-06-02 2001-03-13 Sciclone Pharmaceuticals, Inc. Combination therapy method for treating chronic hepatitis B
WO1995009647A1 (fr) * 1993-10-07 1995-04-13 The George Washington University Medical Center PROCEDE DE TRAITEMENT DU CHOC SEPTIQUE à L'AIDE DE THYMOSINE-α¿1?
TW252045B (fr) * 1993-10-07 1995-07-21 Allan L Goldstein
WO1995012405A1 (fr) * 1993-11-05 1995-05-11 Alpha 1 Biomedicals, Inc. Methode et composition pour le traitement de patients souffrant d'une maladie hepatique decompensee
US6262230B1 (en) 1994-01-28 2001-07-17 Sciclone Pharmaceuticals Inc. Analogs of thymosin α1
JP3853384B2 (ja) * 1994-09-09 2006-12-06 株式会社三菱化学ヤトロン 抗サイモシンα１モノクローナル抗体産生ハイブリドーマ
US5632983A (en) 1994-11-17 1997-05-27 University Of South Florida Method for treating secondary immunodeficiency
AU6164898A (en) * 1997-02-18 1998-09-08 Sciclone Pharmaceuticals, Inc. Use of thymosin alpha 1 for the manufacture of a medicament for promoting stem cell development
US20070025958A1 (en) 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
US20070154399A1 (en) * 2000-10-27 2007-07-05 Hadden John W Immunotherapy for immune suppressed patients
JP2004521867A (ja) * 2000-10-27 2004-07-22 イミュノ−アールエックス， インコーポレイテッド 免疫抑制された患者のためのワクチン免疫療法
PL370453A1 (en) * 2001-10-26 2005-05-30 Rhode Island Hospital Thymosin augmentation of genetic immunization
UA78726C2 (en) * 2001-11-01 2007-04-25 Sciclone Pharmaceuticals Inc Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment
UA77999C2 (en) * 2001-12-10 2007-02-15 Thymosin-alpha 1 for treatment of malignant glioblastoma
CA2506893A1 (fr) 2002-11-25 2004-06-10 Sciclone Pharmaceuticals, Inc. Procedes de protection contre des dommages dus a un rayonnement, faisant appel a la thymosine alpha
NZ542900A (en) 2003-03-28 2007-06-29 Sciclone Pharmaceuticals Inc Treatment of aspergillus infections with thymosin alpha 1
US20100311656A1 (en) * 2003-04-23 2010-12-09 Sciclone Pharmaceuticals, Inc. Treatment or prevention of respiratory viral infections with alpha thymosin peptides
CN1822850A (zh) * 2003-07-18 2006-08-23 雷根内克斯生物制药有限公司 由放射线照射引起的损伤的治疗或预防
WO2005115341A2 (fr) * 2004-05-27 2005-12-08 Advanced Bionutrition Corporation Microparticules pour administration orale
ITRM20060583A1 (it) * 2006-10-27 2008-04-28 Francesco Bistoni Uso della timosina alfa 1 per la preparazione di un medicamento per la prevenzione e la cura delle allergie
WO2009070639A1 (fr) 2007-11-28 2009-06-04 Irx Therapeutics, Inc. Méthode propre à accroître un effet immunologique
US8716012B2 (en) * 2009-05-08 2014-05-06 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers
DK2429585T3 (en) 2009-05-15 2018-07-30 Irx Therapeutics Inc VACCINE IMMUNOTHERAPY
EP2510106B1 (fr) 2009-12-08 2018-02-14 IRX Therapeutics, Inc. Méthode d'inversion de la suppression immunitaire des cellules de langerhans
US20130296223A1 (en) 2012-03-30 2013-11-07 Sciclone Pharmaceuticals, Inc. Use of thymosin alpha for the treatment of sepsis
GB201621732D0 (en) * 2016-12-20 2017-02-01 Agricultural Research Council A multi-epitope dna vaccine for heartwater

Also Published As

Publication number Publication date
US4079127A (en) 1978-03-14
HU172798B (hu) 1978-12-28
ZA775976B (en) 1978-06-28

Similar Documents

Publication Publication Date Title
BE860169A (fr) Thymosine alpha1
DD131094A5 (de) Fluessigkristallzusammensetzungen
AT344629B (de) Siebfeld
ATA204777A (de) Schischu
SE425157B (sv) Koerformig ozonalstrare
AT353866B (de) Hoergeraet
AT349288B (de) Ruehrwerksmuehle
AT359262B (de) Raffstore
ATA505377A (de) Ruehrwerksmuehle
SE7802775L (sv) Fergverksdrivning
SE430308B (sv) Sikt
BR7706948A (pt) Conjunto percussor
AT346259B (de) Webschaft
AT378100B (de) Halmerntegeraet
AT370310B (de) Elektrokardioskop
AR211563A1 (es) Electrolizador
AT349360B (de) Unmagnetische tretmine
AT358854B (de) Kruemelwalze
AT346734B (de) Springmine
AT356609B (de) Kristallisator
AT356871B (de) Saegegatter
AT371411B (de) Skibob
AT346041B (de) Sheddach
AT346049B (de) Bauelement
AT345469B (de) Deodorantien

Legal Events

Date Code Title Description
RE20 Patent expired

Owner name: F. HOFFMANN-LA ROCHE A.G.

Effective date: 19971027

Owner name: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTE

Effective date: 19971027